Elesclomol induces cancer cell apoptosis through oxidative stress

Molecular Cancer Therapeutics

Volumn 7, Issue 8, 2008, Pages 2319-2327

  Kirshner, Jessica R ^a,b   He, Suqin ^a   Balasubramanyam, Vishwasenani ^a   Kepros, Jane ^a   Yang, Chin Yu ^a   Zhang, Mei ^a   Du, Zhenjian ^a   Barsoum, James ^a   Bertin, John ^a,c  

^a Synta Pharmaceuticals Corp   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ELESCLOMOL; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CELL DEATH; GENE INACTIVATION; GENE INDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; OXIDATIVE STRESS; PRIORITY JOURNAL; SKIN METASTASIS; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; GENE EXPRESSION PROFILING; HUMANS; HYDRAZINES; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 53349153454     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0298     Document Type: Article

References (39)

1. Foley KP, Bertin J, Chan K, et al. The oxidative stress inducer STA-4783 enhances the in vivo efficacy of multiple anti-cancer therapies in mouse tumor models [abstract]. In: Program and Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications; 2007 Oct 22-26; San Francisco, CA. Philadelphia (PA): AACR; 2007. p 159. Abstract A290.
2. Berkenblit A, Eder JP, Jr., Ryan DP, et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 2007;13:584-90.
3. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34.
4. Kong Q, Beel JA, Lillehei KO. A threshold concept for cancer therapy. Med Hypotheses 2000;55:29-35.
5. D'Autreaux B, Toledano MB. ROS as signaling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007;8:813-24.
6. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-8.
7. Petros JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A 2005;102:719-24.
8. Suh YA, Arnold RS, Lassegue B, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401:79-82.
9. Huang P, Feng L, OldhamEA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390-5.
10. Pelicano H, Feng L, Zhou Y, et al. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem 2003;278:37 832-9.
11. TrachoothamD, Zhou Y, Zhang H, et al. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate. Cancer Cell 2006;10:241-52.
12. Hase H, Kanno Y, Kojima H, Morimoto C, Okumura K, Kobata T. CD27 and CD40 inhibit p53-independent mitochondrial pathways in apoptosis of B cells induced by B cell receptor ligation. J Biol Chem 2002;277:46950-8.
13. Parsell DA, Lindquist S. The function of heat-shock proteins in stress tolerance: degradation and reactivation of damaged proteins. Annu Rev Genet 1993;27:437-96.
14. Kang YJ. Metallothionein redox cycle and function. Exp Biol Med (Maywood) 2006;231:1459-67.
15. Lecane PS, Karaman MW, Sirisawad M, et al. Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res 2005;65:11676-88.
16. Cotto JJ, Morimoto RI. Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. Biochem Soc Symp 1999;64:105-18.
17. Adams TK, Saydam N, Steiner F, Schaffner W, Freedman JH. Activation of gene expression by metal-responsive signal transduction pathways. Environ Health Perspect 2002;1105Suppl:813-7.
18. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116.
19. Whitesell L, Bagatell R, Falsey R. The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets 2003;3:349-58.
20. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;28:1309-12.
21. Zhang Y, Fong CC, Wong MS, et al. Molecular mechanisms of survival and apoptosis in RAW 264.7 macrophages under oxidative stress. Apoptosis 2005;10:545-56.
22. Filomeni G, Rotilio G, Ciriolo MR. Disulfide relays and phosphorylative cascades: partners in redox-mediated signaling pathways. Cell Death Differ 2005;12:1555-63.
23. KimYH, Park EJ, Han ST, Park JW, Kwon TK. Arsenic trioxide induces Hsp70 expression via reactive oxygen species and JNK pathway in MDA231 cells. Life Sci 2005;77:2783-93.
24. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000;408:239-47.
25. Davis W, Jr., Ronai Z, Tew KD. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther 2001;296:1-6.
26. Li D, Ueta E, Kimura T, Yamamoto T, Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 2004;95:644-50.
27. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999;18:6027-36.
28. Cabello CM, Bair Iii WB, Wondrak GT. Experimental therapeutics: targeting the redox Achilles heel of cancer. Curr Opin Investig Drugs 2007;8:1022-37.
29. Neuzil J, Wang XF, Dong LF, Low P, Ralph SJ. Molecular mechanism of "mitocan"-induced apoptosis in cancer cells epitomizes the multiple roles of reactive oxygen species and Bcl-2 family proteins. FEBS Lett 2006;580:5125-9.
30. 2-terminal kinase (JNK/SAPK). J Biol Chem 1998;273:28253-60.
31. Ramanathan B, Jan KY, Chen CH, Hour TC, Yu HJ, Pu YS. Resistance to paclitaxel is proportional to cellular total antioxidant capacity. Cancer Res 2005;65:8455-60.
32. Alexandre J, Batteux F, Nicco C, et al. Accumulation of hydrogen peroxide is an early and crucial step for paclitaxel-induced cancer cell death both in vitro and in vivo. Int J Cancer 2006;119:41-8.
33. Meyskens FL, Jr., Farmer P, Fruehauf JP. Redox regulation in human melanocytes and melanoma. Pigment Cell Res 2001;14:148-54.
34. Wittgen HG, van Kempen LC. Reactive oxygen species in melanoma and its therapeutic implications. Melanoma Res 2007;17:400-9.
35. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1-3.
36. Portakal O, Ozkaya O, Erden Inal M, Bozan B, Kosan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem2000;33:279-84.
37. Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209-19.
38. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, Baniel J. Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol 2007;178:1238-44.
39. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008;68:1777-85.